The US Food and Drug Administration has approved the antibacterial medicine, Levaquin (levofloxacin), for the treatment of patients with plague, a rare disease that is estimated to affect up to 2,000 people per year. ---Subscribe to MedNous to access this article--- Regulation & Policy
